Skip to main content
SpringerLink
Log in

Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose. To investigate the activity of the combination of gemcitabine (G) plus epirubicin (E) and taxol (T), (GET), in metastatic breast cancer, to evaluate the feasibility of this regimen as induction before high dose chemotherapy and to study the pharmacokinetic interactions of these three drugs.

Patients and methods. Metastatic breast cancer patients, with bidimensionally measurable disease were eligible. Treatment consisted of G 1000mg/sqm days 1 and 4 plus E 90 mg/sqm day 1 plus T 175mg/sqm/3h day 1, every 21 days. After six courses of GET, patients aged less than 60 years, in complete or partial remission or stable disease entered a programme of high dose chemotherapy (HDCT), as consolidation treatment.

Results. Thirtysix patients were included in this study. Grade 4 neutropenia was observed in 64% of the patients, with four episodes of febrile neutropenia; 39% of the patients experienced mild to moderate peripheral neuropathy; grade 2 and 3 mucositis occurred respectively in 9 (25%) and 6 (17%) patients. The overall response rate to GET was 92% (95% CI, 77.53%–98.25%); CR 31% and PR 61%. After six courses of GET, 25 patients received HDCT, leading to an overall response rate of 96% with 58% CR. At a median follow up of 25 months (range 8–39), 13 out of 36 patients are progression free and 26 alive. Median progression free survival is 21 months, while median overall survival has not yet been reached. The pharmacokinetic data show that G does not influence the interactions between E and T, while gemcitabine kinetics remains unchanged.

Conclusions. The results of the present study indicate that the addition of G to E plus T as front line treatment for advanced breast cancer is well tolerated with an ORR of 92%. On the basis of the high activity and interesting progression free and overall survival rates, the GET combination deserves further evaluation in randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Falkson G, Holcroft C, Gelman RS, Tormey DC, Wolter JM, Cummings FJ: Ten-year follow up study of premenopausal women with metastatic breast cancer: an eastern cooperative oncology group study. J Clin Oncol 13: 1453-1458, 1995

    Google Scholar 

  2. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN: Results and long term followup for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85: 104-111, 1999

    Google Scholar 

  3. Norton L, Simon R: The Norton-Simon hypothesis revised. Cancer Treat Rep 70: 163-169, 1986

    Google Scholar 

  4. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L: 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17: 1118-1126, 1999

    Google Scholar 

  5. Sledge GW Jr, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin versus taxol versus doxorubicin plus taxol as first-line therapy for metastatic breast cancer: an intergroup trial. Proc Am Soc Clin Oncol 16: 1a, (abstr), 1997

    Google Scholar 

  6. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3 h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688-2699, 1995

    Google Scholar 

  7. Gehl J, Boesgaard M, Paaske T, Vittrup Jensen B, Dombernowsky P: Combined doxorubic in and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7: 687-693, 1996

    Google Scholar 

  8. Valagussa P, Gianni L, Capri G, Tarenzi E, Villani F, Bonadonna G: Three-year follow up in women with metastatic breast cancer after bolus doxorubicin and paclitaxel infused over 3 h (AT). Proc Am Soc Clin Oncol 17: 111, (abstr 429), 1998

    Google Scholar 

  9. Minotti G, Cavaliere AF, Mordente A, Rossi M, Schiavello R, Zamparelli R, Possati G: Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 95(4): 1595-605, 1995

    Google Scholar 

  10. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 15: 1906-1915, 1997

    Google Scholar 

  11. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M: Dose-finding study and pharmacokinetics of epirubic in and paclitaxel over 3 h: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 15: 2510-2517, 1997

    Google Scholar 

  12. Danesi R, Conte PF, Del Tacca M: Pharmacokinetic optimization of treatment schedules for anthracyclines and paclitaxel in cancer patients. Clin Pharmacokin 37: 195-211, 1999

    Google Scholar 

  13. Aapro MS, Martin C, Hatty S: Gemcitabine-a safety review. AntiCancer Drugs 9: 191-201, 1998

    Google Scholar 

  14. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: a phase II trial with Gemcitabine. J Clin Oncol 13: 2731-2736, 1995

    Google Scholar 

  15. Blackstein M, Vogel CL, Ambinder R, Cowan J, Pearce P, Iglesias J, Dorr FA: Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15: 117, 1996

    Google Scholar 

  16. Mavroudis D, Malamos N, Alexopoulos A, Kourousis C, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonicolis J, Kakolyris S, Samonis G, Georgoulias V: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cooperative Group. Ann Oncol 10: 211-215, 1999

    Google Scholar 

  17. Rothenberg ML, Sharma A, Weiss GR, Villalona-Calero MA, Eckardt JR, Aylesworth C, Kraynak MA, Rinaldi DA, Rodriguez GI, Burris HA III, Eckhardt SG, Stephens CD, Forral K, Nicol SJ, Von Hoff DD: Phase I trial of taxol and gemcitabine administered every 2 weeks in patients with refractory solid tumor. Ann Oncol 9: 733-738, 1999

    Google Scholar 

  18. Garcia-Conde J, Lluch A, Perez-Manga G, Palomero I, Alba E, Rueda A, Moreno-Noguiera JA, Calvo E, Tarazona Y, Lopez-Martin E: Gemcitabine +doxorubicin in advanced breast cancer: final results from an early phase II study. Proc Am Soc Clin Oncol 16: 147a, (abstr), 1997

    Google Scholar 

  19. Luftner D, Flath B, Akrivakis C, Mergenthaler HG, Ohnmacht U, Arning M, Possinger K: Gemcitabine plus dose-escalated epirubic in in advanced breast cancer: results of a phase I study. Invest New Drugs 16: 141-146, 1998

    Google Scholar 

  20. Conte P, Bengala C, Donati S, Baldini E, Pazzagli I, Favre C, Greco F, Orlandini C: Gemcitabine, Epirubicine and Taxol (GET) in metastatic breast cancer: preliminary report of a phase I-II study with pharmacokinetic and peripheral blood progenitor cell (PBPC) mobilization assessment. Proc Am Soc Clin Oncol 17: 134a, (abstr), 1998

    Google Scholar 

  21. Gennari A, Salvadori B, Tognoni A, Conte PF: Rapid intravenous premedication with dexamethasone prevents hypersensivity reactions to paclitaxel. Ann Oncol 7: 977-979, 1996

    Google Scholar 

  22. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981

    Google Scholar 

  23. Abruzzese J, Grunewald R, Weeks EA: A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991

    Google Scholar 

  24. Jamis-Dow CA, Klecker RW, Sarosy G, Reed E, Collins JM: Steady-state plasma concentrations and effects of taxol at a 250mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33: 48-52, 1993

    Google Scholar 

  25. Fogli S, Danesi R, Innocenti F, Di Paolo A, Bocci G, Barbara C, Del Tacca M: An improved method for therapeutic drug monitoring of anthracyclines and their major metabolites in human plasma. Ther Drug Monit 21: 367-375, 1999

    Google Scholar 

  26. Venturini M, Bruzzi P, Del Mastro L, Garrone O, Bertelli G, Guelfi M, Pastorino S, Rosso R, Sertoli MR: Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first line CEF regimen in patients with metastatic breast cancer. J Clin Oncol 14: 764-773, 1996

    Google Scholar 

  27. Conte PF and Gennari A: Anthracyclines-taxol combinations in the treatment of breast cancer. Ann Oncol 8: 939-943, 1997

    Google Scholar 

  28. Gennari A, Salvadori B, Donati S, Bengala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte P: Cardiotoxicity of epirubicin/taxol containing regimens: role of cardiac risk factors. J Clin Oncol 17: 3596-3602, 1999

    Google Scholar 

  29. Stadtmauer EA, O'Neill A, Goldste in LJ, Crilley P, Mangan KF, Ingle JN, Lazarus HM, Erban J, Sickles C, Glick JH: Phase III randomized trial of high dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (PBT-1). Proc Am Soc Clin Oncol 18: 1, (abstr.), 1999

    Google Scholar 

  30. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrincione C, Wood W, Henderson I, Hurd D, Norton L: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol 18: 2, (abstr.), 1999

    Google Scholar 

  31. Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W: Bcl-2 overexpression is associated with resistance to taxol, but not to gemcitabine, in multiple myeloma cells. Int J Oncol 13: 839-848, 1998

    Google Scholar 

  32. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ: Gemcitabine and taxol: pharmacokinetic and pharmacodynamic interactions in patients with non small cell lung cancer. J Clin Oncol 17: 2190-2197, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Santa Chiara Hospital and University, Pisa, Italy

    Pier Franco Conte, Alessandra Gennari, Sara Donati, Barbara Salvadori, Editta Baldini, Carmelo Bengala, Ilaria Pazzagli & Cinzia Orlandini

  2. Division of Pharmacology and Chemotherapy, Department of Oncology, Santa Chiara Hospital and University, Pisa, Italy

    Romano Danesi, Stefano Fogli & Mario Del Tacca

Authors
  1. Pier Franco Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Gennari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Donati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Salvadori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Editta Baldini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carmelo Bengala
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ilaria Pazzagli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Cinzia Orlandini
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Romano Danesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stefano Fogli
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mario Del Tacca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Conte, P.F., Gennari, A., Donati, S. et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study*. Breast Cancer Res Treat 68, 171–179 (2001). https://doi.org/10.1023/A:1011945623464

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1011945623464

Search

Navigation